{
  "source": "PA-Notification-Cometriq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1021-13\nProgram Prior Authorization/Notification\nMedication Cometriq® (cabozantinib)\nP&T Approval Date 02/2013, 07/2013, 8/2014, 8/2015, 6/2016, 6/2017, 6/2018, 6/2019,\n6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nCometriq® (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with\nprogressive, metastatic medullary thyroid cancer (MTC).\nIn addition, the National Cancer Comprehensive Network (NCCN) recommends Cometriq for the\ntreatment of medullary, follicular, oncocytic and papillary thyroid carcinomas. NCCN also\nrecommends Cometriq for the treatment of non-small cell lung cancer (NSCLC) with RET gene\nrearrangement.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Cometriq will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Thyroid Carcinoma\n1. Initial Authorization\na. Cometriq will be approved based on the following criterion:\n(1) One of the following:\n(a) Diagnosis of medullary carcinoma\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(b) All of the following:\ni. Diagnosis of one of the following:\n• Follicular carcinoma\n• Oncocytic cell carcinoma\n• Papillary carcinoma\n-AND-\nii. Disease is progressive after treatment with one of the following:\n• Lenvima (lenvatinib)\n• Nexavar (sorafenib)\n-AND-\niii. Disease is at least one of the following:\n• Symptomatic ",
    "y carcinoma\n-AND-\nii. Disease is progressive after treatment with one of the following:\n• Lenvima (lenvatinib)\n• Nexavar (sorafenib)\n-AND-\niii. Disease is at least one of the following:\n• Symptomatic iodine-refractory\n• Unresectable locoregional recurrent or persistent disease\n• Distant metastatic disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cometriq will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cometriq therapy\nAuthorization will be issued for 12 months.\nC. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Cometriq will be approved based on both of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(2) Positive for RET gene rearrangements\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cometriq will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(1) Patient does not show evidence of progressive disease while on Cometriq therapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cometriq [prescribing information]. Alameda, CA: Exelix",
    "e of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cometriq [prescribing information]. Alameda, CA: Exelixis, Inc.; August 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/ . Accessed May 5, 2025.\nProgram Prior Authorization/Notification - Cometriq (cabozantinib)\nChange Control\n7/2013 Review of clinical criteria. No change to coverage. Updated formatting.\n8/2014 Annual review. Added coverage for NSCLC, clarified thyroid cancer,\nupdated formatting, Background and References.\n8/2015 Annual review with no change to clinical criteria. Increased authorization\nand reauthorization from 11 months to 12 months for all indications.\nUpdated references.\n6/2016 Annual review. Updated MTC clinical criteria to include only a diagnosis\nof MTC. Updated background, formatting and references.\n6/2017 Annual review. Changed MTC clinical criteria to Thyroid Cancer to\ninclude NCCN expanded thyroid cancer indications. Updated background,\nformatting and references.\n6/2018 Annual review. Updated references.\n6/2019 Annual review. Revised criteria for thyroid carcinoma. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n3\n6/2020 Annual review. Updated references.\n6/2021 Annual review. No change to clinical criteria. Updated references.\n6/2022 Annual review. Revised clinical criteria for thyroid carcinomas to align\nwith NCCN indications. Added NCCN Recommended Regimens to\ncoverage criteria. Updated references.\n6/2023 Annual review. Updated Hürthle cell neoplasm to Oncocytic carcinoma in\nbackground and criteria per NCCN guidelines. No change in clinical\nintent of criteria. Updated references and added state mandate footnote.\n6/2024 Annual review. Updated references.\n6/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}